ArticleFrontiers in endocrinology2025
Sugar-sweetened beverage consumption predicts metabolic associated fatty liver disease in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycogen metabolic dysfunction in T2DM with MASLD: linking α-hydroxybutyrate to GYS2 downregulation.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic associated fatty liver disease (MAFLD) is a leading cause of chronic liver disease worldwide, with heightened prevalence and progression risks in individuals with type 2 diabetes mellitus (T2DM). Emerging evidence suggests dietary factors, particularly sugar-sweetened beverage (SSB) consumption, may exacerbate metabolic dysregulation, yet this relationship remains underexplored in MAFLD populations. Method: We enrolled 3,305 T2DM patients from Taizhou University Hospital, classifying them into MAFLD and non-MAFLD groups via liver ultrasonography. SSB consumption was quantified as weekly intake. Clinical parameters and SSB consumption were analyzed using logistic regression. External validation leveraged NHANES data, focusing on total sugar intake and surrogate markers. Results: MAFLD patients exhibited significantly higher BMI, waist/hip ratios, and SSB consumption than non-MAFLD counterparts (p<0.001). SSB consumption emerged as an independent MAFLD risk factor, with dose-dependent escalation in MAFLD odds. The MAFLD model based on glycometabolism (MMBG), integrating SSB consumption, C-peptide, and glucose, outperformed traditional indices, such as TyG, VAI, and AIP, achieving superior AUC (0.712 vs. 0.631-0.666), enhanced clinical utility and higher Brier scores (p<0.05, respectively). NHANES validation confirmed BMI, central obesity, hyperglycemia, and sugar intake as MAFLD predictors. Conclusion: SSB consumption independently predicts MAFLD risk in T2DM patients, with synergistic effects from dysregulated glycometabolism. The MMBG model, incorporating SSB consumption and glycometabolic parameters, offers a robust tool for early MAFLD risk identification and personalized interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.